Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies

Authors


  • Conflicts of Interest

    • JM Carrascosa has been both a member of an advisory board and speaker for AbbVie, Janssen, MSD, Novartis and Pfizer, and acted as an investigator for AbbVie, Amgen, Eli Lilly, Janssen, MSD, Novartis and Pfizer. M van Doorn has acted as a consultant for Abbott, Janssen, LEO Pharma and Pfizer, and has been an investigator for Eli Lilly, Idera Pharmaceuticals and Novartis. D Jullien has been both a member of an advisory board and consultant for Abbott, Eli Lilly, Janssen, MSD, Novartis and Pfizer, and has also been a speaker for Abbott, Janssen, MSD and Pfizer. F Nestle has acted as a consultant for Abbott, AbbVie, Celgene, Janssen, Novartis and Pfizer. J Prinz has been a speaker for Biogen-Idec, MSD, Novartis, Pfizer, Serono and Wyeth, on an advisory board for Novartis, Pfizer and Serono and acted as an investigator for Centocor and Serono.
  • Funding sources

    • This manuscript was developed by an unrestricted grant from Pfizer Inc. Medical writing support was provided by Synergy Medical.

Abstract

Biological drugs such as the tumour necrosis factor inhibitors have revolutionized the treatment of psoriasis, but some have the potential to induce an unwanted immune response. This immunogenicity may be associated with low trough drug levels, reduced clinical efficacy, reduced drug survival and an increased risk for adverse events. This article presents a literature review of the evidence on immunogenicity of biologics used in the treatment of psoriasis and considers the implications for therapeutic decision-making in the management of patients with moderate-to-severe psoriasis.

Ancillary